Company news
Onconetix, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
June 20, 2023
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
June 13, 2023
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 11, 2023
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
May 9, 2023
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
April 25, 2023
Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®
April 24, 2023
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company
April 23, 2023
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
April 19, 2023
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine
April 11, 2023
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
March 8, 2023
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development
February 5, 2023
Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates
January 31, 2023
Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors
January 16, 2023
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco
January 8, 2023
Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both
December 11, 2022
Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate
December 5, 2022
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Cong...
November 30, 2022
Blue Water Vaccines Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate Development from The University of Texas Health San Antonio
November 20, 2022
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
November 9, 2022
Blue Water Vaccines Announces Appointment of Vuk Jeremić, Previous Chair of the Council of Europe’s Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors
November 7, 2022
Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona
October 10, 2022
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
September 20, 2022
Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
September 7, 2022
Blue Water Vaccines to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
August 30, 2022
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
August 23, 2022
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
August 21, 2022
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
August 16, 2022
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 14, 2022
Blue Water Vaccines Announces $10 Million Private Placement Priced At-the-Market under Nasdaq Rules
August 8, 2022
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development
July 19, 2022
Blue Water Vaccines to Present at the JMP Securities Life Science Conference
June 5, 2022
Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
May 30, 2022
Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate
May 18, 2022
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
May 12, 2022
Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
May 11, 2022
Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children’s Research Hospital for Novel Bacterial Vaccine Platform
May 10, 2022
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
April 20, 2022
Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 19, 2022
Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 12, 2022
Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
April 10, 2022
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
March 21, 2022
Blue Water Vaccines Announces Closing of Initial Public Offering
February 22, 2022
Blue Water Vaccines Announces Pricing of approximate $20M Initial Public Offering
February 16, 2022